Mizuho Begins Coverage on Tarsus Pharmaceuticals (NASDAQ:TARS)

Investment analysts at Mizuho assumed coverage on shares of Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) in a research report issued to clients and investors on Thursday, Marketbeat.com reports. The firm set an "outperform" rating and a $100.00 price target on the stock. Mizuho's target price would suggest a potential upside of 29.68% from the stock's previous close.

• 3 Biotech Catalysts Present Major Opportunity

A number of other equities analysts have also recently commented on TARS. Wall Street Zen raised Tarsus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, November 8th. HC Wainwright raised their price target on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the company a "neutral" rating in a research note on Monday, October 20th. Zacks Research raised shares of Tarsus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, September 5th. Guggenheim increased their price target on Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the company a "buy" rating in a research note on Wednesday, November 5th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $74.14.

View Our Latest Stock Analysis on Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ TARS opened at $77.11 on Thursday. The business has a fifty day moving average price of $65.55 and a two-hundred day moving average price of $52.62. The stock has a market capitalization of $3.27 billion, a PE ratio of -38.17 and a beta of 0.82. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.29 and a quick ratio of 4.25. Tarsus Pharmaceuticals has a fifty-two week low of $38.51 and a fifty-two week high of $78.76.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. The firm had revenue of $118.70 million for the quarter, compared to analyst estimates of $114.22 million. As a group, equities analysts predict that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current fiscal year.

Insider Activity at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 6,000 shares of the firm's stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $55.37, for a total transaction of $332,220.00. Following the completion of the transaction, the chief executive officer owned 812,106 shares of the company's stock, valued at approximately $44,966,309.22. This trade represents a 0.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William J. Phd Link sold 27,116 shares of the business's stock in a transaction on Monday, September 8th. The stock was sold at an average price of $57.00, for a total transaction of $1,545,612.00. Following the completion of the sale, the director directly owned 143,332 shares in the company, valued at approximately $8,169,924. This represents a 15.91% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 8.97% of the company's stock.

Institutional Trading of Tarsus Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Victory Capital Management Inc. raised its position in shares of Tarsus Pharmaceuticals by 999.5% in the 1st quarter. Victory Capital Management Inc. now owns 44,320 shares of the company's stock worth $2,277,000 after acquiring an additional 40,289 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Tarsus Pharmaceuticals during the first quarter worth approximately $1,818,000. Thoroughbred Financial Services LLC grew its stake in Tarsus Pharmaceuticals by 16.1% during the first quarter. Thoroughbred Financial Services LLC now owns 5,510 shares of the company's stock worth $283,000 after purchasing an additional 765 shares during the period. Vanguard Group Inc. increased its holdings in Tarsus Pharmaceuticals by 5.3% in the first quarter. Vanguard Group Inc. now owns 2,226,595 shares of the company's stock worth $114,380,000 after purchasing an additional 111,433 shares in the last quarter. Finally, Swiss National Bank lifted its stake in Tarsus Pharmaceuticals by 6.1% in the first quarter. Swiss National Bank now owns 55,533 shares of the company's stock valued at $2,853,000 after buying an additional 3,200 shares during the period. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Featured Stories

• Five stocks we like better than Tarsus Pharmaceuticals
• What is a buyback in stocks? A comprehensive guide for investors
• Why Target Stock May Keep Falling Despite a 5% Dividend Yield
• Investing in the High PE Growth Stocks
• Is Tesla Setting Up for a Year-End Rebound—or a Collapse?
• Top Biotech Stocks: Exploring Innovation Opportunities
• Applied Materials: Up 40% in 2025 With Room to Run Long-Term

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Tarsus Pharmaceuticals Right Now?

Before you consider Tarsus Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.

While Tarsus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here